Early Morphic data hint at a threat to Entyvio
Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Comirnaty is the real deal in the real world
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
J&J’s Covid-19 vaccine set to become third to US
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
A three way battle beckons in GM1 gangliosidosis
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Lynparza’s Olympia win could broaden breast cancer use
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
The big Covid-19 trials still to report
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
